# Five neurology startups, including Oyster Therapeutics, raise around $450 million in recent weeks

- Published: 2026-11-14 08:06 UTC
- Section: Industry & People › Start-ups
- Tags: neurology startups funding, Oyster Therapeutics Series A, brain drug venture capital, central nervous system startups, Cabaletta Bio rese-cel, PepGen myotonic dystrophy, splicing correction, cell therapy stocks
- URL: https://realtech.media/news/rt-59b2f0f543b2f7f2fa630a4b_five_neurology_startups/

**Startups focused on the central nervous system have raised $664 million in 2026 by mid-November, per BioPharma Dive data. Oyster Therapeutics' Series A was $60 million.**

![Five neurology startups, including Oyster Therapeutics, raise around $450 million in recent weeks](https://realtech.media/media/2026/11/8c7cffe6314703fc.jpg)
*U.S. Navy photo by John F. Williams, Wikimedia Commons, Public domain*

Five neurology-focused startups have together raised around $450 million in the last few weeks, BioPharma Dive reported on biopharmadive.com [1]. One of them is London-based Oyster Therapeutics, which said it raised $60 million in a Series A round led by 4BIO Capital [1]. Eight other parties took part, including Eli Lilly [1].

## Funding for brain drug startups

According to data compiled by BioPharma Dive, startups focused on the central nervous system took in $1.09 billion, $1.58 billion and $1.9 billion between 2023 and 2025 from 26 prolific venture firms [1]. The 2026 total is smaller, at $664 million by mid-November [1].

Oyster's aim is to degrade a protein tied to Alzheimer's disease [1]. Four other neuroscience biotechs, Setara Therapeutics, Delix Therapeutics, VectorY Therapeutics and Neurosterix, disclosed fundraising since the end of October. Those rounds collectively brought in around $400 million [1].

## Cell therapy data and market reaction

At the American College of Rheumatology conference this week, cell therapy developers presented data on immune disorders such as lupus and systemic sclerosis [1]. Cabaletta Bio reported early, encouraging results from a trial of its therapy rese-cel across three diseases, and its share price has risen roughly 5% since the market close last week [1].

Shares of Nkarta, Allogene Therapeutics and Fate Therapeutics were all down more than 20% from Nov. 6 to Nov. 12. CRISPR Therapeutics declined nearly 15% [1].

PepGen's experimental treatment for a muscle-wasting illness drew the strongest response. According to the company, a mid-stage study in people with myotonic dystrophy type 1 found that its drug helped repair, on average, 46.5% of the splicing errors that are a genetic hallmark of the disease [1]. PepGen described this as the highest level of splicing correction ever in a multiple-dose study of a drug for this condition, and its stock rose by more than 90% [1].

Leerink Partners analyst Joseph Schwartz wrote that the figure is higher than what researchers have seen with rival therapies from Novartis and Dyne Therapeutics. He added that cross-trial comparisons remain imperfect [1].

## Sources

1. [biopharmadive.com](https://www.biopharmadive.com/news/charts-venture-neuroscience-oyster-vectory-acr-cell-therapy/874570)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-59b2f0f543b2f7f2fa630a4b_five_neurology_startups/